Continues to advance preclinical discovery of its SCN9A research program, anticipates reporting results from initial in vivo animal studies by year-end 2022
Continues progression of work with. | March 25, 2022
– Exicure will reduce its workforce by approximately 50%, along with the implementation of other cost-cutting measures –
– Company to wind down immuno-oncology program cavrotolimod. | December 10, 2021
Exicure, Inc. Announces Results of Internal Investigation and Implementation of Strategic Measures to Reduce Cash Burn and Prioritize Pipeline Focus -Exicure will reduce. | December 10, 2021